Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Mark J, Murphy"'
Autor:
Peter Cornelisse, Daniel S Strasser, Marianne M Martinic, Mark J Murphy, Ouali Berkani, Clélia Cahuzac, Thomas F Hoyler
Publikováno v:
Lupus Science and Medicine, Vol 10, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/7aaa96ba687843b980271de950869e48
Publikováno v:
Platelets, Vol 33, Iss 1, Pp 147-156 (2022)
Here, we report the in vitro characterization of the P2Y12 receptor antagonist selatogrel (ACT-246475). Binding studies with radiolabeled selatogrel demonstrated that selatogrel is a competitive antagonist of ADP binding to the P2Y12 receptor with a
Externí odkaz:
https://doaj.org/article/021492ffe66347039fb420e397888fd0
Autor:
Estelle Gerossier, Saba Nayar, Sylvie Froidevaux, Charlotte G. Smith, Celine Runser, Valentina Iannizzotto, Enrico Vezzali, Gabin Pierlot, Ulrich Mentzel, Mark J. Murphy, Marianne M. Martinic, Francesca Barone
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-19 (2021)
Abstract Background Sjögren’s syndrome is a systemic autoimmune disease characterized by immune cells predominantly infiltrating the exocrine glands and frequently forming ectopic lymphoid structures. These structures drive a local functional immu
Externí odkaz:
https://doaj.org/article/61ff86a6cb164b9daf9e959da2dde53e
Autor:
Emmanuel A. Meyer, Päivi Äänismaa, Eric A. Ertel, Eva Hühn, Daniel S. Strasser, Markus Rey, Mark J. Murphy, Marianne M. Martinic, Laetitia Pouzol, Sylvie Froidevaux, Marcel P. Keller, Eva Caroff
Publikováno v:
Journal of Medicinal Chemistry. 66:4179-4196
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7df504f393165b1ded7be41f0a7150f
https://doi.org/10.1021/acs.jmedchem.3c00074
https://doi.org/10.1021/acs.jmedchem.3c00074
Autor:
Daniel S Strasser, Estelle Gerossier, Virginie Sippel, Ursula Grieder, Andrea Kieninger-Graefitsch, Sylvie Froidevaux, Marten Trendelenburg, Gabin M Pierlot, Enrico Vezzali, Anna K Stalder, Bérengère Renault, Jesper Ryge, Aaron Hart, Ulrich Mentzel, Peter M A Groenen, Marcel P Keller, Marianne M Martinic, Mark J Murphy
Publikováno v:
RMD Open, Vol 6, Iss 2 (2020)
Objectives: SLE is an autoimmune disease characterised by aberrant lymphocyte activation and autoantibody production. This study provides an in-depth preclinical and clinical characterisation of the treatment effect of cenerimod, a sphingosine-1-phos
Externí odkaz:
https://doaj.org/article/74b13847b7f044e2be8ad1ab498686fc
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 1191, p 1191 (2022)
International Journal of Molecular Sciences; Volume 23; Issue 3; Pages: 1191
International Journal of Molecular Sciences; Volume 23; Issue 3; Pages: 1191
Cenerimod is a potent, selective sphingosine 1-phosphate receptor 1 (S1P1) modulator currently investigated in a Phase IIb study in patients with systemic lupus erythematosus (SLE) (NCT03742037). S1P1 receptor modulators sequester circulating lymphoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e225f551d22cb676b697aa67152686b6
https://www.mdpi.com/1422-0067/23/3/1191
https://www.mdpi.com/1422-0067/23/3/1191
Publikováno v:
International journal of molecular sciences. 23(3)
Cenerimod is a potent, selective sphingosine 1-phosphate receptor 1 (S1P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6e3db8e8a3f24806d846a708640c5cfb
https://pubmed.ncbi.nlm.nih.gov/35163112
https://pubmed.ncbi.nlm.nih.gov/35163112
Publikováno v:
Platelets. 33(1)
Here, we report the in vitro characterization of the P2Y12 receptor antagonist selatogrel (ACT-246475). Binding studies with radiolabeled selatogrel demonstrated that selatogrel is a competitive antagonist of ADP binding to the P2Y12 receptor with a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f1a83ae140ba37dee956c764c525544
https://pubmed.ncbi.nlm.nih.gov/33427002
https://pubmed.ncbi.nlm.nih.gov/33427002
Autor:
Akihiko Yokoyama, Francesca Ficara, Mark J Murphy, Christian Meisel, Chikako Hatanaka, Issay Kitabayashi, Michael L Cleary
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e73649 (2013)
The mixed lineage leukemia (MLL) protein is an epigenetic transcriptional regulator that controls proliferative expansion of immature hematopoietic progenitors, whose aberrant activation triggers leukemogenesis. A mature MLL protein is produced by fo
Externí odkaz:
https://doaj.org/article/2ee1c1908c504520b64f99b98bc9750f
Autor:
Alexander J. Engler, Cole R. Edwards, Benjamin M. Younes, Patrick Chai, Alexander Villalobos, Mark J. Murphy, Samuel J. Daugherty-Saunders, Luis A. Ortiz, Donald L. Edberg
Publikováno v:
AIAA Propulsion and Energy 2019 Forum.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebf5e28288a1288b45c99710b142f355
https://doi.org/10.2514/6.2019-3884
https://doi.org/10.2514/6.2019-3884